Selected research
Industry Research
Amlodipine and Olmesartan Industry Research Report 2026
Market perspective
The global Amlodipine and Olmesartan market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Amlodipine and Olmesartan is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Amlodipine and Olmesartan is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Amlodipine and Olmesartan is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Amlodipine and Olmesartan include Teva, Glenmark Pharmaceuticals, Daiichi Sankyo, Torrent Pharmaceuticals, Steris Healthcare PVT Ltd, OLMIO, Matrix Laboratories, Macleods Pharmaceuticals and Jubilant Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Amlodipine and Olmesartan market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Amlodipine and Olmesartan Market by Company
Teva
Glenmark Pharmaceuticals
Daiichi Sankyo
Torrent Pharmaceuticals
Steris Healthcare PVT Ltd
OLMIO
Matrix Laboratories
Macleods Pharmaceuticals
Jubilant Pharma
Aurobindo
Alembic Pharmaceuticals
Ajanta Pharma
Accord Healthcare
Amlodipine and Olmesartan Segment by Type
5/40 mg Tablets
5/20 mg Tablets
10/40 mg Tablets
10/20 mg Tablets
Amlodipine and Olmesartan Segment by Application
Hospital
Drug store
Amlodipine and Olmesartan Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amlodipine and Olmesartan market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Amlodipine and Olmesartan and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amlodipine and Olmesartan.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Amlodipine and Olmesartan manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Amlodipine and Olmesartan by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Amlodipine and Olmesartan in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 5/40 mg Tablets
- 5/20 mg Tablets
- 10/40 mg Tablets
- 10/20 mg Tablets
Applications
- Hospital
- Drug store
Companies covered
- Teva
- Glenmark Pharmaceuticals
- Daiichi Sankyo
- Torrent Pharmaceuticals
- Steris Healthcare PVT Ltd
- OLMIO
- Matrix Laboratories
- Macleods Pharmaceuticals
- Jubilant Pharma
- Aurobindo
- Alembic Pharmaceuticals
- Ajanta Pharma
- Accord Healthcare
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Amlodipine and Olmesartan Market Size (2021-2032)
- 2.2.2 Global Amlodipine and Olmesartan Sales (2021-2032)
- 2.2.3 Global Amlodipine and Olmesartan Market Average Price (2021-2032)
- 2.3 Amlodipine and Olmesartan by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 5/40 mg Tablets
- 2.3.3 5/20 mg Tablets
- 2.3.4 10/40 mg Tablets
- 2.3.5 10/20 mg Tablets
- 2.4 Amlodipine and Olmesartan by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Drug store
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Amlodipine and Olmesartan Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Amlodipine and Olmesartan Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Amlodipine and Olmesartan Revenue of Manufacturers (2021-2026)
- 3.4 Global Amlodipine and Olmesartan Average Price by Manufacturers (2021-2026)
- 3.5 Global Amlodipine and Olmesartan Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Amlodipine and Olmesartan, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Amlodipine and Olmesartan, Product Type & Application
- 3.8 Global Manufacturers of Amlodipine and Olmesartan, Established Date
- 3.9 Global Amlodipine and Olmesartan Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Amlodipine and Olmesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Amlodipine and Olmesartan Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Glenmark Pharmaceuticals
- 4.2.1 Glenmark Pharmaceuticals Company Information
- 4.2.2 Glenmark Pharmaceuticals Business Overview
- 4.2.3 Glenmark Pharmaceuticals Amlodipine and Olmesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Glenmark Pharmaceuticals Amlodipine and Olmesartan Product Portfolio
- 4.2.5 Glenmark Pharmaceuticals Recent Developments
- 4.3 Daiichi Sankyo
- 4.3.1 Daiichi Sankyo Company Information
- 4.3.2 Daiichi Sankyo Business Overview
- 4.3.3 Daiichi Sankyo Amlodipine and Olmesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Daiichi Sankyo Amlodipine and Olmesartan Product Portfolio
- 4.3.5 Daiichi Sankyo Recent Developments
- 4.4 Torrent Pharmaceuticals
- 4.4.1 Torrent Pharmaceuticals Company Information
- 4.4.2 Torrent Pharmaceuticals Business Overview
- 4.4.3 Torrent Pharmaceuticals Amlodipine and Olmesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Torrent Pharmaceuticals Amlodipine and Olmesartan Product Portfolio
- 4.4.5 Torrent Pharmaceuticals Recent Developments
- 4.5 Steris Healthcare PVT Ltd
- 4.5.1 Steris Healthcare PVT Ltd Company Information
- 4.5.2 Steris Healthcare PVT Ltd Business Overview
- 4.5.3 Steris Healthcare PVT Ltd Amlodipine and Olmesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Steris Healthcare PVT Ltd Amlodipine and Olmesartan Product Portfolio
- 4.5.5 Steris Healthcare PVT Ltd Recent Developments
- 4.6 OLMIO
- 4.6.1 OLMIO Company Information
- 4.6.2 OLMIO Business Overview
- 4.6.3 OLMIO Amlodipine and Olmesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 OLMIO Amlodipine and Olmesartan Product Portfolio
- 4.6.5 OLMIO Recent Developments
- 4.7 Matrix Laboratories
- 4.7.1 Matrix Laboratories Company Information
- 4.7.2 Matrix Laboratories Business Overview
- 4.7.3 Matrix Laboratories Amlodipine and Olmesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Matrix Laboratories Amlodipine and Olmesartan Product Portfolio
- 4.7.5 Matrix Laboratories Recent Developments
- 4.8 Macleods Pharmaceuticals
- 4.8.1 Macleods Pharmaceuticals Company Information
- 4.8.2 Macleods Pharmaceuticals Business Overview
- 4.8.3 Macleods Pharmaceuticals Amlodipine and Olmesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Macleods Pharmaceuticals Amlodipine and Olmesartan Product Portfolio
- 4.8.5 Macleods Pharmaceuticals Recent Developments
- 4.9 Jubilant Pharma
- 4.9.1 Jubilant Pharma Company Information
- 4.9.2 Jubilant Pharma Business Overview
- 4.9.3 Jubilant Pharma Amlodipine and Olmesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Jubilant Pharma Amlodipine and Olmesartan Product Portfolio
- 4.9.5 Jubilant Pharma Recent Developments
- 4.10 Aurobindo
- 4.10.1 Aurobindo Company Information
- 4.10.2 Aurobindo Business Overview
- 4.10.3 Aurobindo Amlodipine and Olmesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Aurobindo Amlodipine and Olmesartan Product Portfolio
- 4.10.5 Aurobindo Recent Developments
- 4.11 Alembic Pharmaceuticals
- 4.11.1 Alembic Pharmaceuticals Company Information
- 4.11.2 Alembic Pharmaceuticals Business Overview
- 4.11.3 Alembic Pharmaceuticals Amlodipine and Olmesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Alembic Pharmaceuticals Amlodipine and Olmesartan Product Portfolio
- 4.11.5 Alembic Pharmaceuticals Recent Developments
- 4.12 Ajanta Pharma
- 4.12.1 Ajanta Pharma Company Information
- 4.12.2 Ajanta Pharma Business Overview
- 4.12.3 Ajanta Pharma Amlodipine and Olmesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Ajanta Pharma Amlodipine and Olmesartan Product Portfolio
- 4.12.5 Ajanta Pharma Recent Developments
- 4.13 Accord Healthcare
- 4.13.1 Accord Healthcare Company Information
- 4.13.2 Accord Healthcare Business Overview
- 4.13.3 Accord Healthcare Amlodipine and Olmesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Accord Healthcare Amlodipine and Olmesartan Product Portfolio
- 4.13.5 Accord Healthcare Recent Developments
5 Global Amlodipine and Olmesartan Market Scenario by Region
- 5.1 Global Amlodipine and Olmesartan Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Amlodipine and Olmesartan Sales by Region: 2021-2032
- 5.2.1 Global Amlodipine and Olmesartan Sales by Region: 2021-2026
- 5.2.2 Global Amlodipine and Olmesartan Sales by Region: 2027-2032
- 5.3 Global Amlodipine and Olmesartan Revenue by Region: 2021-2032
- 5.3.1 Global Amlodipine and Olmesartan Revenue by Region: 2021-2026
- 5.3.2 Global Amlodipine and Olmesartan Revenue by Region: 2027-2032
- 5.4 North America Amlodipine and Olmesartan Market Facts & Figures by Country
- 5.4.1 North America Amlodipine and Olmesartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Amlodipine and Olmesartan Sales by Country (2021-2032)
- 5.4.3 North America Amlodipine and Olmesartan Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Amlodipine and Olmesartan Market Facts & Figures by Country
- 5.5.1 Europe Amlodipine and Olmesartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Amlodipine and Olmesartan Sales by Country (2021-2032)
- 5.5.3 Europe Amlodipine and Olmesartan Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Amlodipine and Olmesartan Market Facts & Figures by Country
- 5.6.1 Asia Pacific Amlodipine and Olmesartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Amlodipine and Olmesartan Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Amlodipine and Olmesartan Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Amlodipine and Olmesartan Market Facts & Figures by Country
- 5.7.1 South America Amlodipine and Olmesartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Amlodipine and Olmesartan Sales by Country (2021-2032)
- 5.7.3 South America Amlodipine and Olmesartan Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Amlodipine and Olmesartan Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Amlodipine and Olmesartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Amlodipine and Olmesartan Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Amlodipine and Olmesartan Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Amlodipine and Olmesartan Sales by Type (2021-2032)
- 6.1.1 Global Amlodipine and Olmesartan Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Amlodipine and Olmesartan Sales Market Share by Type (2021-2032)
- 6.2 Global Amlodipine and Olmesartan Revenue by Type (2021-2032)
- 6.2.1 Global Amlodipine and Olmesartan Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Amlodipine and Olmesartan Revenue Market Share by Type (2021-2032)
- 6.3 Global Amlodipine and Olmesartan Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Amlodipine and Olmesartan Sales by Application (2021-2032)
- 7.1.1 Global Amlodipine and Olmesartan Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Amlodipine and Olmesartan Sales Market Share by Application (2021-2032)
- 7.2 Global Amlodipine and Olmesartan Revenue by Application (2021-2032)
- 7.2.1 Global Amlodipine and Olmesartan Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Amlodipine and Olmesartan Revenue Market Share by Application (2021-2032)
- 7.3 Global Amlodipine and Olmesartan Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Amlodipine and Olmesartan Value Chain Analysis
- 8.1.1 Amlodipine and Olmesartan Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Amlodipine and Olmesartan Production Mode & Process
- 8.2 Amlodipine and Olmesartan Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Amlodipine and Olmesartan Distributors
- 8.2.3 Amlodipine and Olmesartan Customers
9 Global Amlodipine and Olmesartan Analyzing Market Dynamics
- 9.1 Amlodipine and Olmesartan Industry Trends
- 9.2 Amlodipine and Olmesartan Industry Drivers
- 9.3 Amlodipine and Olmesartan Industry Opportunities and Challenges
- 9.4 Amlodipine and Olmesartan Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst